Regular Article
Fresh Vein Allograft Survival in Dogs after Cyclosporine Treatment

https://doi.org/10.1006/jsre.1996.0180Get rights and content

Abstract

Synthetic grafts are widely used for peripheral arterial reconstructions when autologous veins are not available, but their results have not been satisfactory. Venous allograft may be used as an alternative to synthetic prostheses. The aim of the study was to explore the immunosuppressive efficacy of Cyclosporine A (CyA) as a means of preventing venous allograft failures and rejection. We utilized 56 mongrel dogs. Immunological incompatibility was checked with the skin graft method. Donor inferior vena cava was transplated into the infrarenal abdominal aorta of recipient animals. One group (group 1, 10 dogs) served as a control and three groups received CyA treatment regimens. Group 2 (10 dogs) received postoperative oral CyA treatment for 30 days. Group 3 (12 dogs) received a vein graft pretreated with a CyA solution without postoperative immunosuppressive therapy. Group 4 (9 dogs) received a vein graft pretreated with a CyA solution and postoperative CyA treatment for 30 days. Allografts were examined at 30 days for patency, aneurysmal dilatation, gross structural changes, inflammatory response, and lymphocytic infiltration. Sex chromatine assessment determined the origin (donor or recipient) of the endothelial cells. The allografts from groups 1 and 3 showed significant aneurysmal dilatation and perivenous inflammation when compared to dogs treated with oral CyA therapy (P< 0.0002). Moreover allografts treated with CyA therapy had a better-developed venous neointima (P< 0.009) with less fibrin (P< 0.02), and thinner medial (P< 0.0009) and adventitial layers (P< 0.02). No significant differences were observed in neointimal thickness among the four groups. Lymphocytic infiltration was greater in the group of animals who did not receive oral CyA therapy (P< 0.0004). Barr bodies status showed significant differences between oral CyA treated groups and nontreated groups (P< 0.0003). Oral CyA therapy reduced aneurysmal dilatation and immunological response, promoted the development of a neoendothelium, and preserved the structure of the venous layers. Graft pretreatment with CyA flushing did not have a significant immunosuppressive effect.

References (0)

Cited by (16)

  • Fresh Cold-Stored Vascular Allografts in Subgenicular Location: Our Experience with Rescue Endovascular Techniques

    2022, Annals of Vascular Surgery
    Citation Excerpt :

    A meta-analysis suggests that there are probably no statistically significant differences between the different types of allografts.15 Allografts are very resistant to infection, but at the same time they are antigenic and there are various studies evaluating immunosuppression and its effect on reducing antigenicity and improving the patency of reconstructions.16,17 Some studies compare the immunogenicity of cryopreserved and fresh cold-stored allografts, but the results are inconclusive.18

  • Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model

    2017, International Journal of Pharmaceutics
    Citation Excerpt :

    On the other hand, there are frequent problems associated with the use of allografts, such as the increased risk of disease transmission between individuals. Further, Oschner and co-workers studied the use of such grafts and identified that rejection was a recurring occurrence in some patients (Mingoli et al., 1996). As a matter of fact, the antigenicity of the cryopreserved grafts is not decreased by the process of cryopreservation as evidenced by in vivo studies (Moriyama et al., 2001).

  • Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model

    2016, International Journal of Pharmaceutics
    Citation Excerpt :

    On the other hand, there are frequent problems associated with the use of allografts, such as the increased risk of disease transmission between individuals. Further, Oschner and co-workers studied the use of such grafts and identified that rejection was a recurring occurrence in some patients (Mingoli et al., 1996). As a matter of fact, the antigenicity of the cryopreserved grafts is not decreased by the process of cryopreservation as evidenced by in vivo studies (Moriyama et al., 2001).

  • The Positive Effect of Immunosuppression on Adaptation of Venous Allografts to Arterialisation in Rats

    2010, European Journal of Vascular and Endovascular Surgery
    Citation Excerpt :

    However, given alone, neither cyclosporine A at a 10 mg kg−1 per day nor mycophenolate mofetil at 20 mg kg−1 per day improved the overall patency of venous allografts. In the work of Mingoli et al.,10 cyclosporine A at 20 mg kg−1 day reduced aneurysmal dilatation and immunological responses at 30 days following allogeneic venous transplantations in dogs. However, discontinuing cyclosporine A immunosuppression led to the occlusion of cold-stored17 as well as cryopreserved18 venous allografts within 30 days.

  • Cold-stored Venous Allografts in the Treatment of Critical Limb Ischaemia

    2007, European Journal of Vascular and Endovascular Surgery
    Citation Excerpt :

    Recent immunological studies have shown that venous allografts, cold-stored as well as cryopreserved, are antigenic24 and that the antigenicity is not modified by cryopreservation.25–27 Immunosuppression has been examined as a possible adjunct to decrease the antigenicity of the venous allograft, mainly in animal models.28–30 The immunosuppressive therapy after allovenous reconstructions is generally not used.

View all citing articles on Scopus
View full text